BRIEF—Sun Pharma launches Ilumya in the USA

Sun Pharmaceutical has launched its moderate-to-severe psoriasis treatment Ilumya (tildrakizumab-asmn) in the USA. The interleukin-23 (IL-23) inhibitor was approved in March based on a Phase III study which showed sustained skin clearance in 67.6% of patients.

Chief executive Abhay Gandhi said: "The availability of Ilumya is an important milestone for Sun Pharma as we expand our specialty medicine portfolio in the USA.”

“We understand the importance of patient and physician choice, and are committed to making Ilumya among the most cost-effective treatments on the market today."